Biosimilars Rheumatology Roundup for January 2023—Podcast Edition
On this episode of Not So Different, we reminisce about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
On this episode of Not So Different, we reminisced about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
